ANIKA THERAPEUTICS INC (ANIK) Stock Price, Forecast & Analysis
USA - NASDAQ:ANIK - US0352551081 - Common Stock
ANIK Key Statistics, Chart & Performance
The current stock price of ANIK is 10.13 USD. In the past month the price increased by 10.71%. In the past year, price decreased by -41.28%.
ANIK Latest News, Press Relases and Analysis
ANIK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.2 | 404.03B | ||
| AMGN | AMGEN INC | 15.48 | 182.30B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.77 | 110.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.22 | 72.62B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 897.51 | 60.00B | ||
| INSM | INSMED INC | N/A | 40.88B | ||
| NTRA | NATERA INC | N/A | 29.04B | ||
| BIIB | BIOGEN INC | 9.63 | 23.63B | ||
| INCY | INCYTE CORP | 16.81 | 21.07B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.41 | 20.78B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.09 | 14.55B |
Related stock screener links
About ANIK
Company Profile
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 288 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Company Info
ANIKA THERAPEUTICS INC
32 Wiggins Ave
Bedford MASSACHUSETTS 01730 US
CEO: Cheryl R. Blanchard
Employees: 288
Phone: 17814579000
ANIKA THERAPEUTICS INC / ANIK FAQ
What does ANIK do?
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 288 full-time employees. The firm is leveraging its core expertise in hyaluronic acid and implant solutions. The company partners with clinicians to provide minimally invasive products that restore active living for people around the world. The company is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. The company is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Can you provide the latest stock price for ANIKA THERAPEUTICS INC?
The current stock price of ANIK is 10.13 USD.
What is the dividend status of ANIKA THERAPEUTICS INC?
ANIK does not pay a dividend.
What is the ChartMill rating of ANIKA THERAPEUTICS INC stock?
ANIK has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about ANIKA THERAPEUTICS INC (ANIK) stock?
8 analysts have analysed ANIK and the average price target is 15.81 USD. This implies a price increase of 56.07% is expected in the next year compared to the current price of 10.13.
What is the expected growth for ANIK stock?
The Revenue of ANIKA THERAPEUTICS INC (ANIK) is expected to decline by -25.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for ANIK stock?
The outstanding short interest for ANIKA THERAPEUTICS INC (ANIK) is 2.25% of its float.
ANIK Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ANIK. When comparing the yearly performance of all stocks, ANIK is a bad performer in the overall market: 82.1% of all stocks are doing better.
ANIK Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ANIK. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability.
ANIK Financial Highlights
Over the last trailing twelve months ANIK reported a non-GAAP Earnings per Share(EPS) of -2.28. The EPS increased by 53.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.3% | ||
| ROE | -41.05% | ||
| Debt/Equity | 0 |
ANIK Forecast & Estimates
8 analysts have analysed ANIK and the average price target is 15.81 USD. This implies a price increase of 56.07% is expected in the next year compared to the current price of 10.13.
For the next year, analysts expect an EPS growth of 36.93% and a revenue growth -25.9% for ANIK